The increased expression of FOXO4 was also demonstrated in other DLBCL cell lines (OCI-Ly10, Riva, and U2932) when doxorubicin- and phenylbutyrate-treated surviving cells were analyzed (Supplementary Figure S3). This evidence concerns the gene FOXO4 and diffuse large B-cell lymphoma.